DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter ...
Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something important about this glucose monitoring specialist? DexCom shares last closed ...
Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...
Good morning, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Thanks for joining us at the first session to kick off the 2026 JPMorgan Healthcare Conference. I'll give a warm welcome to ...
DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to Underweight from Equal Weight with a price target of $71, which was brought ...
Jake Leach, Dexcom CEO, joins 'Closing Bell Overtime' to talk its 2026 outlook, the impact of GLP-1s, new devices and more. Got a confidential news tip? We want to hear from you. Sign up for free ...
Hosted on MSN
DexCom's Q4 2025 earnings: What to expect
San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. Valued at $27.4 billion by market ...
For the first time in a decade, DexcomDXCM has a new chief executive. And, to say Jake Leach has his work cut out for him is underselling it. Dexcom stock toppled almost 15% in 2025, pulling back ...
We might earn a commission if you make a purchase through one of the links. The McClatchy Commerce Content team, which is independent from our newsroom, oversees this content. Choosing the right CPA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results